New agents for AML and MDS

作者：Grant Steven^*

来源：Best Practice & Research Clinical Haematology, 2009, 22(4): 501-507.

DOI：10.1016/j.beha.2009.08.003

• acute myeloid leukaemia (AML)
• myelodysplastic syndromes (MDS)
• FMS-like tyrosine kinase receptors (FLT3 inhibitors)
• farnesyl transferase inhibitor (FTI)
• clofarabine
• histone deacetylase (HDAC)
• DNMT
• mTOR
• parthenolide
• PIM kinase

The heterogeneity of acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) has led to a multiplicity of treatments, from cytotoxic agents to signal transduction modulators, cell-cycle inhibitors and epigenetic therapies. While some have shown promising initial results, the outlook for AML patients, particularly older and relapsed patients, as well as patients whose cells exhibit certain adverse chromosomal abnormalities or mutant oncoproteins, continues to be grim. Combination chemotherapy using new agents that act at a number of different levels may provide the greatest potential for successful future therapies. A select number of new agents, approaches and combinations are reviewed here.

• 出版日期2009-12